Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials
The Journal of Dermatology · 2024-10 · 51 (10) · 1269-1278
DOI: 10.1111/1346-8138.17423 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Dermatology, online erschienen am 16.08.2024. Verfasst von Atsuyuki Igarashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Igarashi Dermatology Higashigotanda, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tapinarof is a non‐steroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream (1%) in Japanese patients aged ≥18 years with plaque psoriasis in two phase 3 trials, ZBA4‐1 and ZBA4‐2. ZBA4‐1 ( N = 158) consisted of a 12‐week, double‐blind, vehicle‐controlled treatment period (period 1) and a 12‐week extension treatment period (period 2). Patients were randomized 2:1 to tapinarof or vehicle in period 1; subsequently, all patients who were enrolled in period 2 received tapinarof. ZBA4‐2 ( N = 305) was a 52‐week, open‐label, uncontrolled trial in which all patients received tapinarof. In period 1 of ZBA4‐1, the proportion of patients who achieved a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) with ≥2‐grade improvement from baseline at week 12 (PGA treatment success, the primary endpoint) was 20.06% in the tapinarof group and 2.50% in the vehicle group ( p = 0.0035). The proportion of patients with ≥75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (PASI75 response, a key secondary endpoint) was 37.7% in the tapinarof group and 3.8% in the vehicle group ( p < 0.0001). In ZBA4‐2, PGA treatment success rate was 30.0% at week 12, 51.3% at week 24, and 56.3% at week 52, and PASI75 response rate was 50.4% at week 12, 77.5% at week 24, and 79.9% at week 52, indicating that efficacy responses improved over time and were maintained over 52 weeks. Across the two trials, most adverse events (AEs) were mild or moderate; common AEs included folliculitis and contact dermatitis. In summary, tapinarof cream (1%) was efficacious and generally safe for up to 52 weeks of treatment in Japanese patients with plaque psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Igarashi Dermatology Higashigotanda, Tokyo, Japan.
- Research and Clinical Center for Yusho and Dioxin, Kyushu University, Fukuoka, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Japan Tobacco Inc., Tokyo, Japan.
ORCID-Profile: Shuichi Fukasawa
Zitieren
APA
Igarashi, A., Tsuji, G., Fukasawa, S., Murata, R., & Yamane, S. (2024). Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials. The Journal of Dermatology, 51(10), 1269-1278. https://doi.org/10.1111/1346-8138.17423
Vancouver
Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials. The Journal of Dermatology. 2024;51(10):1269-1278. doi:10.1111/1346-8138.17423
BibTeX
@article{Igarashi2024,
author = {Igarashi, Atsuyuki and Tsuji, Gaku and Fukasawa, Shuichi and Murata, Ryusei and Yamane, Satoshi},
title = {Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials},
journal = {The Journal of Dermatology},
year = {2024},
volume = {51},
number = {10},
pages = {1269--1278},
doi = {10.1111/1346-8138.17423}
}
EUVIMED